AveXis logo

AveXis

Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.

est. 2013

VS
Neurogene Inc. logo

Neurogene Inc.

Reimagining the future for rare neurological diseases

130 employees · est. 2018 · New York, United States

AveXis is the older company (2013 vs 2018).

Side-by-Side Comparison

AveXis Neurogene Inc.
Founded
2013 older 2018
Headquarters
Not tracked yet New York, United States
Employees
Not tracked yet 130
Industry
Biotechnology, Health Care Biotechnology
Funding Stage
Grant Unknown
Total Funding
$75.10M $478.50M
Funding Rounds
5 5
Services
Not tracked yet Gene therapy development, Proprietary transgene regulation technology, Clinical research and trials, Patient and family support, Manufacturing of genetic medicines
Target Customers
Not tracked yet Patients with rare neurological diseases, Families of patients, Healthcare professionals, Biotechnology and pharmaceutical partners, Investors
Taxonomy
Gene Therapy, Neurological Genetic Diseases, Rare Diseases, Medical Innovation, Novartis, Acquisition, Life-Threatening Conditions, Research & Development, Therapeutic Innovations Rare Neurological Diseases, Genetic Medicines, Genomics Revolution, Neurological Disorders, Therapeutics Development, Gene Therapy, Pediatric Neurology, Developmental Delay, Medical Innovation, Global Collaboration, Rare Disease Solutions, Precision Medicine, Patient-Centric Approach
Website
avexis.com neurogene.com
AveXis logo

About AveXis

AveXis is a biotechnology startup specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly. Founded in 2013, the company was later acquired by Novartis on May 14, 2018, and adopted the name Novartis Gene Therapies in 2020. AveXis focuses on dev...

Neurogene Inc. logo

About Neurogene Inc.

Neurogene Inc., founded in 2018, is making significant strides in the Biotechnology sector by developing genetic medicines aimed at treating rare neurological diseases. With the slogan "Reimagining the future for rare neurological diseases," the company is on a mission to address unmet medical needs...

We will tell you when either one moves

BounceWatch watches AveXis and Neurogene Inc. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at AveXis and Neurogene Inc. — by email.

Frequently Asked Questions

AveXis — Specializing in groundbreaking gene therapies for rare neurological genetic diseases, impacting lives profoundly.. Neurogene Inc. — Reimagining the future for rare neurological diseases. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
AveXis has raised $75.10M while Neurogene Inc. has raised $478.50M.
AveXis and Neurogene Inc. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare AveXis with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at AveXis on 11 Sep 2024, and Neurogene Inc. on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy